表紙
市場調査レポート

ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) 市場およびパイプラインの分析:2015年

Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 337530
出版日 ページ情報 英文 180 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) 市場およびパイプラインの分析:2015年 Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015
出版日: 2015年08月19日 ページ情報: 英文 180 Pages
概要

当レポートでは、ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) 市場について調査分析し、HDAC阻害剤の紹介と分類、機序、市場ダイナミクス、世界市場の展望、企業・症状・フェーズ別の臨床パイプライン、臨床パイプライン、前臨床段階における多数派、および上市済み薬 (Beleodaq, Istodax & Zolinza) について、体系的な情報を提供しています。

第1章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) のイントロダクション

第2章 ヒストンデアセチラーゼ (HDAC) の分類

  • クラスI HDAC
  • クラスIIa HDAC
  • クラスIIb HDAC
  • クラスIV HDAC

第3章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) の分類

  • ヒドロキサメート
  • 環状ペプチド
  • 脂肪酸
  • ベンズアミド

第4章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) のメカニズム

第5章 世界のヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) 市場展望

  • 市場の現況
  • ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) パイプラインの概要

第6章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) 市場のダイナミクス

  • 好ましい市場指標
  • 商業化の課題

第7章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤)の将来の展望

第8章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤)の臨床パイプライン:企業、症状およびフェーズ別

  • 研究
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 登録済み

第9章 ヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) の臨床考察:企業・症状別

  • Belinostat (Beleodaq)
  • Romidepsin (Istodax)
  • Vorinostat (Zolinza)

第10章 中止・停止されたヒストンデアセチラーゼ阻害剤 (HDAC阻害剤) の臨床考察

  • 開発報告無し
  • 中止
  • 停止

第11章 競合情勢

  • 4SC
  • Acetylon Pharmaceuticals
  • Astellas Pharma
  • Celleron Therapeutics
  • Chipscreen Biosciences
  • Chroma Therapeutics
  • Chong Kun Dang Pharmaceutical
  • CrystalGenomics
  • Curis
  • Digna Biotech
  • Evgen
  • Johnson & Johnson Pharmaceutical Research and Development
  • Italfarmaco
  • MEI Pharma
  • Mirati Therapeutics
  • Novartis
  • Onxeo
  • Orchid Chemicals and Pharmaceuticals
  • Pharmacyclics
  • Repligen
  • TetraLogic Pharmaceuticals

図表リスト

目次

Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments.

HDAC inhibitors are being developed for different malignancies and some of these products have been in global market for more than decade. New products for different diseases are being introduced in market. Most of them have been developed for oncological application while few products have been introduced in neurology category. Investigational HDAC inhibitors are being developed for HIV, autoimmune, inflammatory disease and other ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years.

HDAC inhibitor market for cancer treatment for hematological malignancies and that to for lymphoma is quite competitive. Besides, Vorinostat and Istodax there is another drug for lymphoma called Beleodaq is available in this segment. Beleodaq is a novel pan HDAC inhibitor for treatment of fast-growing type of Non-Hodgkin Lymphoma (NHL)and Peripheral T-Cell Lymphoma (PTCL). It is expected that due to similar mechanism they will offer competition to each other in coming years. Competition is also expected to be offered by monoclonal antibodies which are already known for their superior pharmacological efficacy. In this scenario, HDAC inhibitor developers have to improve drug design and pharmacological profiles in order to survive in this market segment. Their costs are somewhat lesser then monoclonal antibodies due to which patients belonging to different financial background are expected to choose them as part of their therapeutic regime.

Novel HDAC inhibitors are also being discovered by investigators but their pharmacological and commercialization potential remains elusive. Some of them are already established in global market and others are being revisited for their therapeutics efficacy in other disease segments. Hydroxamates are one of the largest segment of HDAC inhibitors which have made their niche in cancer market segment. Other categories are also being developed for different ailments due to their role in blocking different HDAC members. It could be observed that they belong to different biological groups like aliphatic acids and cyclopeptides. On the other hand, synthetic derivatives are also available which could be easily modified by chemical processes. This fact shows that investigators have plethora of choices that will help them in development of suitable pharmaceutical product having high commercialization potential. However, lots of work is required in this segment for occupying major market shares and competing with previously available therapeutics.

"Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015" Report Highlights:

  • Introduction & Classification Histone Deacetylase (HDAC) Inhibitors
  • Mechanism of Histone Deacetylase (HDAC) Inhibitors
  • Histone Deacetylase (HDAC) Inhibitors Market Dynamics
  • Global Histone Deacetylase (HDAC) Inhibitor Market Outlook
  • Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase
  • Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline: 63
  • Majority of Histone Deacetylase (HDAC) Inhibitor in Preclinical Phase: 35
  • Marketed Histone Deacetylase (HDAC) Inhibitors: 3 (Beleodaq, Istodax & Zolinza)

Table of Contents

1. Introduction to Histone Deacetylase (HDAC) Inhibitors

2. Classification of Histone Deacetylase (HDAC)

  • 2.1 Class I HDAC
  • 2.2 Class IIa HDAC
  • 2.3 Class IIb HDAC
  • 2.4 Class IV HDAC

3. Classification of Histone Deacetylase (HDAC) Inhibitors

  • 3.1 Hydroxamates
  • 3.2 Cyclic Peptides
  • 3.3 Aliphatic Acids
  • 3.4 Benzamides

4. Mechanism of Histone Deacetylase (HDAC) Inhibitors

5. Global Histone Deacetylase (HDAC) Inhibitor Market Outlook

  • 5.1 Curent Market Scenario
  • 5.2 Histone Deacetylase (HDAC) Pipeline Overview

6. Histone Deacetylase (HDAC) Inhibitors Market Dynamics

  • 6.1 Favorable Market Parameters
  • 6.2 Commercialization Challenges

7. Histone Deacetylase (HDAC) Inhibitors Future Prospects

8. Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase-I
  • 8.4 Phase-I/II
  • 8.5 Phase-II
  • 8.6 Phase-III
  • 8.7 Registered

9. Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication

  • 9.1 Belinostat (Beleodaq)
  • 9.2 Romidepsin (Istodax)
  • 9.3 Vorinostat (Zolinza)

10. Discontinued & Suspended Histone Deacetylase (HDAC) Inhibitor Clinical Insight

  • 10.1 No Development Reported
  • 10.2 Discontinued
  • 10.3 Suspended

11. Competitive Landscape

  • 11.1 4SC
  • 11.2 Acetylon Pharmaceuticals
  • 11.3 Astellas Pharma
  • 11.4 Celleron Therapeutics
  • 11.5 Chipscreen Biosciences
  • 11.6 Chroma Therapeutics
  • 11.7 Chong Kun Dang Pharmaceutical
  • 11.8 CrystalGenomics
  • 11.9 Curis
  • 11.10 Digna Biotech
  • 11.11 Evgen
  • 11.12 Johnson & Johnson Pharmaceutical Research and Development
  • 11.13 Italfarmaco
  • 11.14 MEI Pharma
  • 11.15 Mirati Therapeutics
  • 11.16 Novartis
  • 11.17 Onxeo
  • 11.18 Orchid Chemicals and Pharmaceuticals
  • 11.19 Pharmacyclics
  • 11.20 Repligen
  • 11.21 TetraLogic Pharmaceuticals

List of Figures

  • Figure 1-1: Properties of HDAC
  • Figure 1-2: Therapeutic Utility of HDAC Inhibitors
  • Figure 1-3: Benefits of HDAC Inhibitors
  • Figure 1-4: Limitation of HDAC Inhibitors
  • Figure 2-1: Classification of HDAC
  • Figure 3-1: Classification of HDAC Inhibitors
  • Figure 4-1: Mechanism of Vorinostat
  • Figure 4-2: Mechanism of Panobinostat
  • Figure 4-3: Mechanism of Resminostat
  • Figure 4-4: Mechanism of Entinostat
  • Figure 5-1: Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
  • Figure 5-2: Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
  • Figure 5-3: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
  • Figure 5-4: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
  • Figure 6-1: HDAC Inhibitors Market Favorable Parameters
  • Figure 6-2: HDAC MarketCommercialization Challenges
  • Figure 11-1: 4SC Clinical Pipeline
  • Figure 11-2: Celleron Therapeutics Clinical Pipeline
  • Figure 11-3: Curis Clinical Pipeline
  • Figure 11-4: DIGNA Biotech Clinical Pipeline
  • Figure 11-5: Onxeo Clinical Pipeline
  • Figure 11-6: TetraLogic Pharmaceuticals Clinical Pipeline

List of Tables

  • Table 1-1: Few Important HDACi under Development for Different Indications
  • Table 3-1: HDAC Inhibitors Belonging to Different Classes
  • Table 4-1: FDA Approved HDACi for Lymphoma
Back to Top